Zolmitriptan is the 5HT1-receptor agonist drug prescribed to treat migraine. The Zolmitriptan binds the specifically to the serotonin (5-HT) 1B receptors that results in narrowing the blood vessels connecting brain and thereby inhibiting the pain signals from the brains. These result in blocking the release of the pro-inflammatory neuropeptide that cause headache, nausea and related symptoms. This drug limits the pain caused due to acute migraine attacks however, it is not efficient to prevent the migraine attack. Commercially, it is available in tablet form, orally disintegrating tablet and a nasal spray to improve the migraine symptoms.
- Rise in prevalence of Migraine
- Side Effects of zolmitriptan
The key Players profiled in the report are AstraZeneca (United Kingdom), Glenmark (India), Amneal Pharmaceuticals, Inc. (United States), Zydus Cadila (India), Zosano Pharma Corporation (United States), Teva Pharmaceutical Industries Ltd. (Israel), Viatris Inc. (United States), Aurobindo Pharma Limited (India), Sun Pharmaceutical Industries Limited (India) and INKE (Spain).